Drug Trial Radar · NCT07806175
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
486
Planned (sponsor's estimate)
Start
Sep 15, 2026
Primary completion
Aug 15, 2028
Study completion Aug 15, 2029
Sponsor
- Lead sponsor
- Rongchang Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
Conditions
- Advanced Malignant Solid Tumors
Interventions
RCZY690 TabletsDrug
Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.
RCZY690 tablesDrug
Oral medication. The patient will continue treatment until unacceptable toxic reactions occur, the disease progresses, or any criteria for leaving the study are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting ToxicityTime frame: 24 months
- Number of subjects with adverse events (AEs)Time frame: 24 months
- Maximum Tolerated Dose and/or Maximum Administered DoseTime frame: 24 months
- Recommended Phase 2 DoseTime frame: 24 months
- Objective Response Rate (ORR)Time frame: 24 months
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Cancer Hospital, CAMS
Beijing, Beijing Municipality, China
Hunan Provincial Cancer Hospital
Hunan, Changsha, China
Zhejiang Cancer Hospital
Zhejiang, Hangzhou, China
Shandong Cancer Hospital
Shandong, Jinan, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Shanxi Provincial Cancer Hospital
Shanxi, Taiyuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.